BACKGROUND: Salivary gland carcinomas of the larynx are rare, and account for < 1% of laryngeal malignancy. The purpose of this study is to review our management experience of salivary gland carcinomas of the larynx in Taipei Veterans General Hospital and to compare it with other major existing series. METHODS: From 1981 to 2000, 11 patients with laryngeal salivary gland carcinomas treated in Taipei Veterans General Hospital were included in this study. Their demographic data, treatment modalities, survival, and failure pattern, obtained by review of medical records, were analyzed. RESULTS: All 11 patients were male. Median follow-up period was 95 months (range, 18-181 months). The 5-year overall survival rate of all patients was 71%, and the 5-year disease-specific survival rate was 83%. CONCLUSION: The mainstay treatment of laryngeal salivary gland carcinomas in these cases was surgery or surgery with postoperative radiotherapy. The survival rate was satisfactory and similar to that of squamous cell carcinoma of the larynx.
BACKGROUND:Salivary gland carcinomas of the larynx are rare, and account for < 1% of laryngeal malignancy. The purpose of this study is to review our management experience of salivary gland carcinomas of the larynx in Taipei Veterans General Hospital and to compare it with other major existing series. METHODS: From 1981 to 2000, 11 patients with laryngeal salivary gland carcinomas treated in Taipei Veterans General Hospital were included in this study. Their demographic data, treatment modalities, survival, and failure pattern, obtained by review of medical records, were analyzed. RESULTS: All 11 patients were male. Median follow-up period was 95 months (range, 18-181 months). The 5-year overall survival rate of all patients was 71%, and the 5-year disease-specific survival rate was 83%. CONCLUSION: The mainstay treatment of laryngeal salivary gland carcinomas in these cases was surgery or surgery with postoperative radiotherapy. The survival rate was satisfactory and similar to that of squamous cell carcinoma of the larynx.
Authors: Andrés Coca-Pelaz; Leon Barnes; Alessandra Rinaldo; Antonio Cardesa; Jatin P Shah; Juan P Rodrigo; Carlos Suárez; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Bruce M Wenig; Primož Strojan; Marc Hamoir; Patrick J Bradley; Douglas R Gnepp; Carl E Silver; Pieter J Slootweg; Asterios Triantafyllou; Vincent Vander Poorten; Michelle D Williams; Alena Skálová; Henrik Hellquist; Afshin Teymoortash; Jesus E Medina; K Thomas Robbins; Karen T Pitman; Luiz P Kowalski; Remco de Bree; William M Mendenhall; Robert P Takes; Alfio Ferlito Journal: Adv Ther Date: 2016-03-19 Impact factor: 3.845